These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20699624)

  • 41. [A case report of S-1 monotherapy for advanced hepatocellular carcinoma].
    Yamashita T; Arai K; Terashima T; Sunagozaka H; Shimakami T; Yamashita T; Mizukoshi E; Sakai A; Honda M; Kaneko S
    Gan To Kagaku Ryoho; 2012 Sep; 39(9):1435-7. PubMed ID: 22996786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.
    Nabhan C; Lestingi TM; Galvez A; Tolzien K; Kelby SK; Tsarwhas D; Newman S; Bitran JD
    Urology; 2009 Sep; 74(3):665-71. PubMed ID: 19616281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer.
    Keisner SV; Shah SR; Jean GW; Ussery SM; Dowell JE
    Ann Pharmacother; 2010 Oct; 44(10):1538-44. PubMed ID: 20841515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
    Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
    Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.
    Hayakawa N; Matsumoto K; Sato A; Sakamoto H; Ezaki T; Maeda T; Ninomiya A; Nakamura S
    Int Urol Nephrol; 2014 Jun; 46(6):1123-9. PubMed ID: 24356920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival.
    Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Bamias A; Dimopoulos MA
    Anticancer Res; 2011 Apr; 31(4):1475-82. PubMed ID: 21508406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.
    Sonpavde G; Aparicio A; Guttierez I; Boehm KA; Hutson TE; Berry WR; Asmar L; von Hoff DD
    Clin Genitourin Cancer; 2007 Dec; 5(7):457-9. PubMed ID: 18272030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diethylstilbestrol in castration-resistant prostate cancer.
    Wilkins A; Shahidi M; Parker C; Gunapala R; Thomas K; Huddart R; Horwich A; Dearnaley D
    BJU Int; 2012 Dec; 110(11 Pt B):E727-35. PubMed ID: 23110500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer.
    Venkitaraman R; Thomas K; Huddart RA; Horwich A; Dearnaley DP; Parker CC
    BJU Int; 2008 Feb; 101(4):440-3. PubMed ID: 17941935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer.
    Vogiatzi P; Claudio PP
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1027-30. PubMed ID: 20645691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
    Rathkopf D; Liu G; Carducci MA; Eisenberger MA; Anand A; Morris MJ; Slovin SF; Sasaki Y; Takahashi S; Ozono S; Fung NK; Cheng S; Gan J; Gottardis M; Obermeier MT; Reddy J; Zhang S; Vakkalagadda BJ; Alland L; Wilding G; Scher HI;
    Clin Cancer Res; 2011 Feb; 17(4):880-7. PubMed ID: 21131556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
    Bratt O; Häggman M; Ahlgren G; Nordle O; Björk A; Damber JE
    Br J Cancer; 2009 Oct; 101(8):1233-40. PubMed ID: 19755981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting the future in castration-resistant prostate cancer.
    Verhagen P
    Lancet Oncol; 2009 Mar; 10(3):201-2. PubMed ID: 19261249
    [No Abstract]   [Full Text] [Related]  

  • 54. Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.
    Vogelhuber M; Feyerabend S; Stenzl A; Suedhoff T; Schulze M; Huebner J; Oberneder R; Wieland W; Mueller S; Eichhorn F; Heinzer H; Schmidt K; Baier M; Ruebel A; Birkholz K; Bakhshandeh-Bath A; Andreesen R; Herr W; Reichle A
    Cancer Microenviron; 2015 Apr; 8(1):33-41. PubMed ID: 25503648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells.
    Das TP; Suman S; Damodaran C
    Mol Carcinog; 2014 Jul; 53(7):537-47. PubMed ID: 23475579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study.
    Akaza H; Ikemoto I; Namiki M; Usami M; Kobayashi M; Fujimoto H; Tsukamoto T; Naito S
    Oncology; 2010; 78(5-6):323-8. PubMed ID: 20699624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Usami M; Fujimoto H; Akaza H
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1065-70. PubMed ID: 20157711
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
    Miyake H; Hara I; Yamazaki H; Eto H
    Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.